Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys.

The Journal of Pharmacology and Experimental Therapeutics
Daniel F ManvichLeonard L Howell

Abstract

Accumulating evidence indicates that the serotonin system modulates the behavioral and neurochemical effects of cocaine, but the receptor subtypes mediating these effects remain unknown. Recent studies have demonstrated that pharmacological activation of the serotonin 2C receptor (5-HT(2C)R) attenuates the behavioral and neurochemical effects of cocaine in rodents, but such compounds have not been systematically evaluated in nonhuman primates. The present experiments sought to determine the impact of pretreatment with the preferential 5-HT(2C)R agonist m-chlorophenylpiperazine (mCPP) and the selective 5-HT(2C)R agonist Ro 60-0175 [(α-S)-6-chloro-5-fluoro-α-methyl-1H-indole-1-ethanamine fumarate] on the behavioral and neurochemical effects of cocaine in squirrel monkeys. In subjects trained to lever-press according to a 300-s fixed-interval schedule of stimulus termination, pretreatment with either 5-HT(2C)R agonist dose-dependently and insurmountably attenuated the behavioral stimulant effects of cocaine. In subjects trained to self-administer cocaine, both compounds dose-dependently and insurmountably attenuated cocaine-induced reinstatement of previously extinguished responding in an antagonist-reversible manner, and the sele...Continue Reading

References

Dec 1, 1994·Journal of Clinical Psychopharmacology·S L WalshG E Bigelow
Jul 28, 1997·The Journal of Comparative Neurology·K Eberle-WangM F Chesselet
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E ErikssonH Nissbrandt
Oct 9, 1999·Pharmacology, Biochemistry, and Behavior·R D SpealmanT V Khroyan
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Paul W CzotyLeonard L Howell
Oct 10, 2002·Psychopharmacology·Charles W SchindlerSteven R Goldberg
May 8, 2004·The Journal of Pharmacology and Experimental Therapeutics·Malgorzata FilipKathryn A Cunningham
May 21, 2004·Nature Reviews. Neuroscience·Roy A Wise
Mar 3, 2005·Pharmacology, Biochemistry, and Behavior·Brett C GinsburgLeonard L Howell
Jan 30, 2007·Pharmacology, Biochemistry, and Behavior·Heather L KimmelLeonard L Howell
Mar 21, 2007·Neuroscience·M J Bubar, K A Cunningham
Apr 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sylvia NavaillesUmberto Spampinato
Jul 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paul J FletcherGuy A Higgins
Sep 6, 2008·Progress in Brain Research·Marcy J Bubar, Kathryn A Cunningham
Aug 26, 2009·Pharmacology, Biochemistry, and Behavior·Rayna M BauzoLeonard L Howell
Sep 22, 2009·Pharmacology, Biochemistry, and Behavior·Heather L KimmelLeonard L Howell
May 15, 2010·The Journal of Pharmacology and Experimental Therapeutics·K S MurnaneL L Howell
Mar 8, 2011·The European Journal of Neuroscience·Marie-Josée WallmanMartin Parent

❮ Previous
Next ❯

Citations

Sep 18, 2013·Trends in Pharmacological Sciences·Guy A HigginsPaul J Fletcher
Jul 9, 2013·Journal of Pharmacological and Toxicological Methods·K V ThrivikramanMichael J Owens
Sep 14, 2014·Expert Opinion on Drug Discovery·Sandra M W van de WielJudith R Homberg
Dec 1, 2015·Pharmacology & Therapeutics·Giuseppe Di Giovanni, Philippe De Deurwaerdère
Apr 23, 2014·British Journal of Pharmacology·Christina J PerryAndrew J Lawrence
Apr 29, 2014·Behavioural Brain Research·Christian P Müller, Judith R Homberg
Apr 15, 2015·ACS Chemical Neuroscience·Guy A Higgins, Paul J Fletcher
Apr 30, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caleb J Browne, Paul J Fletcher
Sep 20, 2011·Neuroscience·N Albelda, D Joel
Jan 22, 2017·ACS Chemical Neuroscience·Harshini NeelakantanKathryn A Cunningham
Dec 18, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maylen Perez DiazLeonard L Howell
Jul 20, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caleb J BrowneColin Harvey-Lewis
Dec 3, 2016·Journal of Psychopharmacology·Clinton E Canal, Kevin S Murnane
Nov 20, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthew L Banks, S Stevens Negus
Oct 27, 2017·Journal of Psychopharmacology·Guy A HigginsPaul J Fletcher
Sep 7, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maylen Perez DiazLeonard L Howell
Dec 9, 2017·The Journal of Pharmacology and Experimental Therapeutics·Brenda M GannonGregory T Collins
May 13, 2014·The Journal of Pharmacology and Experimental Therapeutics·Debra A CooperLeonard L Howell
Dec 17, 2014·Pharmacological Reviews·Leonard L Howell, Kathryn A Cunningham
Sep 28, 2017·Behavioural Pharmacology·Vanessa Minervini, Charles P France
Mar 8, 2020·Neuropharmacology·Noelle C AnastasioKathryn A Cunningham
Dec 17, 2017·Neuropharmacology·Gregory T CollinsCharles P France

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.